Pharmaceutical Executive Editorial Staff from Pharmaceutical Executive - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare		FDA Issues Complete Response Letter to Astellas for Zolbetuximab BLA for GEJ Adenocarcinoma - 10 months ago FDA Grants Priority Review to Pfizer and Genmab's Tivdak for Cervical Cancer Treatment - 10 months ago ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation for Ovarian Cancer - 10 months ago Novartis Announces Positive Findings for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia - 10 months ago Zelix Pharmaceuticals Files BLA for PET Imaging Agent for Renal Cell Carcinoma - 10 months ago Pivotal Phase III Trials to Evaluate Four Promising Agents in Merck's Oncology, Hematology Pipeline - 10 months ago Setting the Stage for Specialty Drugs in 2024: Q&A with Tina Fresta, Strategic Solutions Senior Manager at epocrates - 10 months ago CVS to Remove Humira From Some Reimbursement Lists in Favor of Biosimilar Options - 10 months ago Eli Lilly Launches Telehealth Platform to Sell Certain Drugs Directly to Consumers - 10 months ago FDA Grants Fast Track, Breakthrough Designations to CG Oncology Inc’s Cretostimogene Grenadenorepvec - 10 months ago Invivyd Seeks EUA for Monoclonal Antibody Designed to Prevent COVID-19 in Immunocompromised Individuals - 11 months ago FDA Fast Tracks Candel Therapeutics' Novel Treatment for Pancreatic Ductal Adenocarcinoma - 11 months ago AstraZeneca Bolsters Cellular Therapy Pipeline With Acquisition of Gracell Biotechnologies - 11 months ago FDA Grants Priority Review to Genentech's sBLA for Xolair to Treat Food Allergies - 11 months ago FDA Accepts Biologics License Application for CSL Behring’s Garadacimab for Hereditary Angioedema - 11 months ago FDA Approves Filsuvez for Epidermolysis Bullosa - 11 months ago Merck's 21-Valent Pneumococcal Conjugate Vaccine Granted FDA Priority Review - 11 months ago FDA Approves Expanded Indication for LEO Pharma's Adbry for Pediatric Patients With Atopic Dermatitis - 11 months ago Moderna's Novel mRNA Vaccine Shows Significant Efficacy Against RSV - 11 months ago GSK's Jemperli Plus Zejula Produces Significant Survival Improvement in Endometrial Cancer - 11 months ago Arcutis Biotherapeutics, Inc’s Zoryve Gets FDA Approval for Seborrheic Dermatitis - 11 months ago FDA Approves Padcev/Keytruda Combo for Locally Advanced, Metastatic Urothelial Cancer - 11 months ago Erasca’s Naporafenib Gets FDA Fast Track Designation for Metastatic Melanoma - 11 months ago Moderna and Merck's Novel Cancer Vaccine, Keytruda Combo Cuts Risk of Skin Cancer Death, Recurrence by Half - 11 months ago CDC Raises Urgent Alert for Low Vaccination Coverage for COVID-19, Influenza, RSV - 11 months ago FDA Approves Merck's Welireg for Advanced Renal Cell Carcinoma - 11 months ago FDA Approves First Treatment Indicated to Lower Risk of Relapse in Pediatric Patients With High-Risk Neuroblastoma - 11 months ago Pfizer Clears Final Regulatory Hurdles to Acquire Seagen Inc - 11 months ago MAPS Seeks Approval of First Psychedelic-Assisted Therapy for PTSD - 11 months ago AstraZeneca Strengthens Respiratory Illness Pipeline With Acquisition of Icosavax - 11 months ago Bristol Myers Squibb to Pay Up to $8.4 Billion to Codevelop Antibody-Drug Conjugate With SystImmune - 11 months ago Merck and Moderna to Launch Trial of mRNA-4157 Plus Keytruda in Non-Small Cell Lung Cancer - 11 months ago FDA Expands Indication of Cresemba for Use in Children With Invasive Aspergillosis, Invasive Mucormycosis - 11 months ago FDA Approves Two Landmark Cell-Based Gene Therapies for Sickle Cell Disease - 11 months ago Prevalence of Eight Chronic Health Conditions Reach Unprecedented Levels in US - 11 months ago Teva's Ajovy Shows Similar Efficacy Reducing Migraine Attacks in Patients With Obesity - 11 months ago Merck Halts Phase 3 Trial of Keytruda Combination for Non-Small Cell Lung Cancer - 11 months ago Merck Halts Phase III Trial of Keytruda Combination for Non-Small Cell Lung Cancer - 11 months ago CVS Becomes Latest PBM to Overhaul Drug Pricing Formula - 11 months ago FDA Approves Novartis’ Fabhalta for Paroxysmal Nocturnal Hemoglobinuria - 11 months ago Eli Lilly Announces Availability of Obesity Drug Zepbound at US Pharmacies - 11 months ago FDA Grants Breakthrough Designation to Johnson & Johnson’s Novel Treatment for HR-NMIBC - 12 months ago FDA Grants Priority Review to Bristol Myers Squibb's Opdivo Combination for Urothelial Carcinoma - 12 months ago Roche Bolsters Obesity, Diabetes R&D Portfolio With Acquisition of Carmot Therapeutics - 12 months ago FDA Approves Lilly's Jaypirca for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma - 12 months ago FDA Grants Priority Review to Keytruda Plus Padcev for Urothelial Carcinoma - 12 months ago FDA Fast Tracks eFFECTOR Therapeutics' Zotatifin Combo for ER+/HER2– Breast Cancer - 12 months ago AbbVie to Acquire ImmunoGen With its Platinum-Resistant Ovarian Cancer Drug Elahere - 12 months ago FDA Accepts Arcutis Biotherapeutics' sNDA for Roflumilast Cream for Atopic Dermatitis - 12 months ago FDA Issues Warning of Potential Adverse Events Associated With Antiseizure Drugs - 12 months ago